文献速递产科母胎医学

QUiPP App在三个独立欧洲有症状孕妇队列中的外部验证

External validation of QUiPP App in three independent European cohorts of symptomatic women.
PubMed 文献 · Ultrasound Obstet Gynecol · 2025-06-26

在三个欧洲独立队列(前瞻性多中心452例、荷兰回顾性单中心581例、比利时回顾性单中心399例)中外部验证QUiPP App v.2预测有症状孕妇自发性早产。联合模型预测1周内早产AUC在欧洲队列为0.84、荷兰队列为0.74,比利时队列CL-only模型AUC为0.80;低风险校准良好,较高风险者风险常被低估。

要点

  • QUiPP App v.2联合宫颈长度与定量胎儿纤连蛋白模型预测1周内自发性早产AUC在欧洲队列为0.84、荷兰队列为0.74。
  • 比利时队列仅验证宫颈长度模型,预测1周内自发性早产AUC为0.80。
  • 预测短期结局(如<30周)性能优于长期结局(如<37周),欧洲队列CL+qfFN预测<30周AUC最高为0.91。

核心结论

  • QUiPP App v.2可为预测低风险的自发性早产患者提供 reassurance,且对短期结局的预测性能优于长期结局。
  • 尽管与原始QUiPP数据集的患病率存在显著差异,联合CL+qfFN模型和qfFN-only模型表现尚可。
  • 对失访患者进行统计校正改善了CL预测因子的判别能力。

研究设计与样本

  • 外部验证研究,在三个独立数据集验证QUiPP App v.2:前瞻性欧洲多中心队列(5个国家,n=452)、荷兰回顾性单中心队列(n=581)、比利时回顾性单中心队列(n=399)。
  • 纳入2012年至2023年间在三级医院就诊、孕23至34周有早产症状的孕妇。
  • 通过输入定量胎儿纤连蛋白和/或宫颈长度及其他危险因素计算风险估计;比利时队列因无纤连蛋白检测试剂盒仅验证基于CL的QUiPP模型。
  • 欧洲队列无缺失病例;荷兰队列因数据缺失仅分析完整病例;比利时队列使用逆概率删失加权对失访患者进行统计校正。
  • 采用ROC曲线分析三个QUiPP模型(qfFN单独、CL单独、CL+qfFN)在六个预设时间点(检测后1、2、4周内,以及<30、<34、<37周妊娠)预测sPTB风险;使用5%、10%、15%风险阈值计算敏感度、特异度及阳性/阴性似然比;评估模型校准。

主要发现

  • 预测检测后1周内sPTB,CL+qfFN联合模型在欧洲队列AUC为0.84(95%CI 0.79-0.89),荷兰队列AUC为0.74(95%CI 0.66-0.83);比利时队列CL-only模型AUC为0.80(95%CI 0.75-0.85)。
  • 对短期结局(如sPTB<30周)的预测性能优于长期结局(如sPTB<37周)。
  • 欧洲队列中CL+qfFN模型预测sPTB<30周AUC最高,为0.91(95%CI 0.86-0.95)。
  • 校准:对风险可忽略的患者校准极佳;但对sPTB较高风险女性,预测风险普遍低于观察事件率。

关键数值与推荐

  • 预测检测后1周内sPTB的AUC:欧洲队列CL+qfFN模型0.84(95%CI 0.79-0.89),荷兰队列CL+qfFN模型0.74(95%CI 0.66-0.83)。
  • 比利时队列CL-only模型预测检测后1周内sPTB的AUC为0.80(95%CI 0.75-0.85)。
  • 欧洲队列CL+qfFN模型预测sPTB<30周的AUC最高为0.91(95%CI 0.86-0.95)。
  • 使用风险阈值5%、10%、15%计算敏感度、特异度及阳性/阴性似然比。

临床怎么用

  • QUiPP App v.2可为预测低风险的自发性早产患者提供 reassurance。
  • 该工具对短期结局的预测性能优于长期结局。
  • 对较高风险女性,预测风险常被低估,需结合临床评估。

局限性

  • 比利时队列因缺乏纤连蛋白检测试剂盒,仅能验证基于宫颈长度的QUiPP模型。
  • 荷兰队列因数据缺失仅分析完整病例。
  • 与原始QUiPP数据集相比患病率存在显著差异。
  • 对较高风险女性,预测风险普遍低于观察事件率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To validate externally the QUantitative Innovation in Predicting Preterm birth (QUiPP) App v.2 for the prediction of spontaneous preterm birth (sPTB) in symptomatic women attending tertiary care in Europe. METHODS: The QUiPP App v.2 was validated in three independent datasets: a prospective European multicenter cohort across five countries (n = 452), a retrospective single-center cohort in The Netherlands (n = 581) and a retrospective single-center cohort in Belgium (n = 399). The cohorts consisted of pregnant women between 23 and 34 weeks' gestation with symptoms of threatened preterm birth attending a tertiary care hospital between 2012 and 2023. We calculated risk estimates using the QUiPP App v.2 by inputting quantitative fetal fibronectin (qfFN) and/or cervical length (CL) measurement, in addition to other risk factors. As a result of the absence of a fibronectin detection kit in the Belgian cohort, only the QUiPP model based on CL could be validated in this dataset. The European cohort had no missing cases, but for the Dutch cohort, only complete cases were analyzed due to missing data. For the Belgian cohort, we statistically corrected for patients lost to follow-up using inverse probability of censoring weighting. Discrimination was assessed using receiver-operating-characteristics (ROC)-curve analysis of three QUiPP models (qfFN alone, CL alone and CL plus qfFN) for the risk of sPTB at six predefined timepoints: within 1, 2 and 4 weeks after testing, and at < 30, < 34 and < 37 weeks' gestation. Sensitivity, specificity and positive and negative likelihood ratios were calculated using risk thresholds of 5%, 10% and 15%. Model calibration was assessed to evaluate the agreement between expected and observed outcomes. RESULTS: The predictive performance of the QUiPP App v.2 for sPTB within 1 week after testing had an area under the ROC curve (AUC) of 0.84 (95% CI, 0.79-0.89) and 0.74 (95% CI, 0.66-0.83) in the European and Dutch cohorts, respectively, using the combined model of CL plus qfFN, and 0.80 (95% CI, 0.75-0.85) in the Belgian cohort using the CL-only model. Predictive performance was greater for shorter-term outcomes, specifically sPTB < 30 weeks, compared with longer-term outcomes, such as sPTB < 37 weeks. The highest AUC (0.91 (95% CI, 0.86-0.95)) was achieved by the model using CL plus qfFN for the prediction of sPTB < 30 weeks in the European cohort. Calibration was excellent for patients with negligible risk; however, for women at greater risk of sPTB, the risk was generally underestimated compared with the observed event rate. CONCLUSIONS: The QUiPP App v.2 offers reassurance for patients with low predicted risk of sPTB and has greater predictive performance for shorter-term, compared with longer-term, outcomes. Despite significant differences in prevalence from the original QUiPP dataset, the model combining CL plus qfFN and the qfFN-only model perform reasonably well. Statistical correction for patients lost to follow-up in the dataset comprising censored and uncensored patients improved the discriminative ability of the CL predictor. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Fischer AM, Bos K, Bakker PCAM, et al. External validation of QUiPP App in three independent European cohorts of symptomatic women. Ultrasound Obstet Gynecol. 2025. PMID: 40568915. doi:10.1002/uog.29263

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。